(Reuters) – Listed here are some upcoming occasions of curiosity to the well being neighborhood. All occasions are native.
Monday, Aug. 2
9 a.m. – The primary bellwether trial is scheduled to start earlier than Chief U.S. District Choose Edmund Sargus in Columbus, Ohio in multidistrict litigation over Becton, Dickinson and Co subsidiary C.R. Bard’s hernia mesh. Plaintiff Steven Johns alleges he was implanted with the corporate’s Ventralight ST hernia mesh and subsequently suffered a recurrence of the hernia, ache and decreased mobility after the machine failed. His case is one in all greater than 13,000 consolidated within the MDL. Tuesday’s listening to may even embody a case administration convention for the MDL.
The bellwether case is Johns v. C.R. Bard et al, No. 18-cv-01509, and the MDL is In re: Davol Inc/C.R. Bard Inc Polypropylene Hernia Mesh Merchandise Legal responsibility Litigation, No. 18-md-02846, U.S. District Courtroom, Southern District of Ohio.
For plaintiffs: David Butler of Taft Stettinius & Hollister.
For Bard: Lori Cohen of Greenberg Traurig.
10 a.m. – Apotex Inc, Fresenius Kabi and Viatris Inc will urge the Federal Circuit U.S. Courtroom of Appeals to invalidate patents on Eagle Prescription drugs Inc’s chemotherapy drug Bendeka, offered in partnership with Teva Pharmaceutical Industries Ltd. The businesses say that U.S. District Choose Colm Connolly in Delaware ought to have discovered the patents invalid as apparent or indefinite. The argument will likely be held telephonically.
The case is Cephalon Inc v. Slayback Pharma Ltd, Federal Circuit U.S. Courtroom of Appeals, No. 20-2134.
For Teva and Eagle: David Berl of Williams & Connolly.
For Apotex: Steven Feldman of Hahn Loeser & Parks.
For Fresenius Kabi and Viatris: Imron Aly of Schiff Hardin.
10 a.m. – The Federal Circuit U.S. Courtroom of Appeals will hear telephonic oral arguments in a patent infringement case introduced by Adapt Pharma accusing Teva Pharmaceutical Industries Ltd of copying Narcan, its extensively used opioid overdose nasal spray therapy. Adapt argues that U.S. District Choose Brian Martinotti in New Jersey improperly dominated its patents apparent following a bench trial on the grounds that every claimed patent limitation may very well be present in prior artwork, with out absolutely contemplating whether or not an individual of atypical talent would have been motivated to mix them.
The case is Adapt Pharma Operations v. Teva Prescription drugs USA Inc, Federal Circuit U.S. Courtroom of Appeals, No. 20-2106.
For Adapt: Catherine Stetson of Hogan Lovells.
For Teva: John Rozendaal of Sterne Kessler Goldstein & Fox.
Tuesday, Aug. 3
10 a.m. – Orthodontics firm SmileDirectClub LLC will urge the Federal Circuit U.S. Courtroom of Appeals to revive a patent lawsuit in opposition to rival Candid Care Co. SmileDirectClub accused the corporate of infringing a patent protecting its technique, which is on the core of its enterprise mannequin, of scanning a affected person’s mouth at a quick appointment and utilizing the scan to make a customized orthodontic machine, which is then mailed to the affected person. SmileDirectClub argues U.S. District Choose Colm Connolly in Delaware wrongly dismissed the case after discovering the patent was directed to an unpatentable summary concept earlier than declare development or discovery. The argument will likely be held telephonically.
The case is SmileDirectClub LLC v. Candid Care Co, Federal Circuit U.S. Courtroom of Appeals, No. 21-1446.
For SmileDirectClub: Simeon Papacostas of Benesch Friedlander Coplan & Aronoff.
For Candid Care: Michael Sandonato of Venable.
Wednesday, Aug. 4
2 p.m. – A case administration convention is scheduled through videoconference earlier than U.S. District Choose Jon Tigar in Oakland, California in litigation over claims that Gilead Sciences Inc’s HIV medicine Viread, Truvada, Atripla, Complera and Stribild trigger harm to sufferers’ kidneys and bones. Plaintiffs allege that Gilead was conscious the merchandise have been unsafe however hid the danger from shoppers whereas making billions from the medicine.
The case is Holley v. Gilead Sciences Inc, U.S. District Courtroom, Northern District of California, No. 18-cv-06972.
For plaintiffs: Steve Berman of Hagens Berman Sobol Shapiro.
For Gilead: Debra Pole of Sidley Austin.
Thursday, Aug. 5
9:15 a.m. – A trial is scheduled to start earlier than U.S. District Choose Matthew Kennelly in Chicago in a case introduced by a person who alleges he had a coronary heart assault because of utilizing AbbVie Inc’s testosterone alternative drug AndroGel. The plaintiff, Brad Martin, is one in all fewer than 100 plaintiffs remaining in a multidistrict litigation over testosterone alternative merchandise alleged hyperlink to cardiovascular issues after AbbVie settled greater than 4,000 circumstances in 2018. Martin’s case was chosen as a bellwether trial. AbbVie received a number of earlier bellwether trials, and received two giant verdicts in opposition to it overturned.
The bellwether case is Martin et al v. Actavis Inc et al, U.S. District Courtroom, No. 15-cv-04292; the MDL is In re Testosterone Alternative Remedy Merchandise Legal responsibility Litigation, U.S. District Courtroom, Northern District of Illinois, No. 14-cv-1748.
For Martin: James O’Brien of O’Brien Legislation.
For AbbVie: Jeffrey Peck of Ulmer & Berne.
Know of an occasion that may very well be included in Week Forward in Well being? Contact Brendan Pierson at brendan.pierson@thomsonreuters.com
